Atara Biotherapeutics(ATRA) - 2025 Q2 - Quarterly Results

Filing Information This section provides the official identification details and securities information for the registrant, Atara Biotherapeutics, Inc Registrant Details This section provides the official identification details for Atara Biotherapeutics, Inc. as the registrant for this Form 8-K filing, including its incorporation state, address, and contact information - Registrant: Atara Biotherapeutics, Inc.[1] - Incorporation Jurisdiction: Delaware[1] - Principal Executive Offices: 2380 Conejo Spectrum Street Suite 200, Thousand Oaks, California 91320[1] Securities Information This part details the registrant's securities registered under Section 12(b) of the Act, specifically its Common Stock, and confirms its status regarding emerging growth company provisions Securities Registered Under Section 12(b) | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :-------------------------------------- | | Common Stock, par value $0.0001 per share | ATRA | The Nasdaq Stock Market LLC | - The registrant is not an emerging growth company.[5] Current Report Items This section outlines preliminary financial estimates, regulatory and business updates for Tabelecleucel, and lists accompanying exhibits Item 2.02 Results of Operations and Financial Condition Atara Biotherapeutics, Inc. announced preliminary estimates for its cash, cash equivalents, and short-term investments as of June 30, 2025. The company explicitly stated that this is a preliminary estimate and does not provide a complete understanding of its financial condition or results of operations for the second quarter - Preliminary estimate of cash, cash equivalents, and short-term investments as of June 30, 2025, was announced on July 14, 2025.[6] - The preliminary estimate does not present all necessary information for a complete understanding of the Company's financial condition or results of operations for the second quarter ended June 30, 2025.[6] Item 8.01 Other Events The Company issued a press release on July 14, 2025, providing updates on the regulatory and business status of its product, Tabelecleucel (Tab-cel®). This press release is filed as an exhibit to the 8-K - On July 14, 2025, the Company issued a press release titled 'Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)'.[7] - The press release is filed as Exhibit 99.1 and incorporated by reference.[7] Item 9.01 Financial Statements and Exhibits This section lists the exhibits accompanying the Form 8-K filing, which include the press release mentioned in Item 8.01 and the interactive data file for the cover page Exhibits | Exhibit No. | Description | | :------------ | :---------------------------------------------- | | 99.1 | Press release, dated July 14, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | Signatures This section formally confirms the authorization and signing of the report by the company's executive leadership Signatures The report is formally signed on behalf of Atara Biotherapeutics, Inc. by its President and Chief Executive Officer, AnhCo Nguyen, Ph.D., confirming due authorization for the filing - The report was signed on July 14, 2025.[12] - Signed by AnhCo Nguyen, Ph.D., President and Chief Executive Officer of ATARA BIOTHERAPEUTICS, INC.[13]